Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2009

View Archived Issues

Astellas Pharma discloses TrkA tyrosine kinase inhibitors for the treatment of urinary conditions

Janssen describes prokineticin-1 receptor antagonists for the treatment of gastrointestinal diseases

Hsp27 inhibitor OGX-427 well tolerated, affects tumor markers in phase I study

AVI BioPharma and CFI sign additional drug development contract for AVI-5038 in DMD

Boehringer Ingelheim discovers phosphodiesterase 4B inhibitors for the treatment of COPD

DSMB recommends continuation of phase III trial comparing Avexa's ATC to 3TC in HIV

Novel sphingosine-1-phosphate receptor agonists described by Pfizer

Novel calcium channel blockers emerge from Pfizer R&D

Belatacept shows immunosuppressant activity in phase II/III studies in kidney transplant recipients

NIAID initiates trial evaluating AEOL-10150 for treating radiation exposure

EyeGate Pharma reports that EGP-437 improves signs and symptoms of dry eye

Pharming receives EMEA agreement on pediatric investigation plan for Rhucin

CNTO-328 shows acceptable safety and promising activity in phase II trials in CRPC and MM patients

Ancora receives phase I SBIR grant from NIH to research SMA vaccine

ACT signs exclusive license for anticancer therapeutic from University of Louisville

Cytopia completes 3-year research term under 2006 collaboration with Novartis

Somaxon resubmits NDA for insomnia drug Silenor to FDA

CDA-1 and CDB-1 show efficacy in phase II study in C. difficile diarrhea

Phase II data on olaparib in breast, ovarian cancer reported at ASCO

Single i.v. dose of BG-9928 displays minimal effect on cardiac conduction in healthy volunteers

Nebivolol does not affect hemoglobin levels in chronic heart failure patients; SENIORS data suggest

Rolofylline fails to demonstrate efficacy for acute heart failure in phase III PROTECT study

PolyMedix initiates dosing in second phase I systemic antibiotic trial

Anadys initiates strategic restructuring to focus on development of ANA-598 in hepatitis C

FDA grants orphan drug designation to Delcath's melphalan for neuroendocrine tumors

Lpath receives grant from the NCI to use for lead candidate Asonep

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...